This company has been marked as potentially delisted and may not be actively trading. NASDAQ:ALIM Alimera Sciences (ALIM) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisFDA EventsInsider TradesTrendsBuy This Stock About Alimera Sciences Stock (NASDAQ:ALIM) Get Alimera Sciences alerts:Sign Up Key Stats Today's Range$5.54▼$5.5450-Day Range$5.19▼$5.6052-Week Range$2.61▼$5.65VolumeN/AAverage Volume376,318 shsMarket Capitalization$290.24 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Alimera Sciences, Inc., a pharmaceutical company, develops and commercializes prescription ophthalmic retinal pharmaceuticals. It operates through United States, International, and Operating Cost segments. The company offers ILUVIEN, a fluocinolone acetonide intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and can lead to severe vision loss and blindness; and to prevent relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye (NIU-PS). It also provides YUTIQ, a fluocinolone acetonide intravitreal implant to treat NIU-PS. The company sells its products to physician offices, clinics, pharmacies, and hospitals through direct sales and distributors. It has a collaboration agreement with EyePoint Pharmaceuticals US, Inc. to develop, manufacture, and sell products including YUTIQ for the treatment and prevention of uveitis; and Ocumension (Hong Kong) Limited for the development and commercialization of the company's 190 microgram fluocinolone acetonide intravitreal implant in applicator for the treatment and prevention of eye diseases. Alimera Sciences, Inc. was incorporated in 2003 and is headquartered in Alpharetta, Georgia. Read More Receive ALIM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Alimera Sciences and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ALIM Stock News HeadlinesANI Pharmaceuticals Expands Ophthalmology Reach As Valuation Signals Upside PotentialMarch 21, 2026 | finance.yahoo.comANI Pharmaceuticals Reshapes Portfolio With Alimera Deal And Rare Disease PushMarch 2, 2026 | finance.yahoo.comThe 1934 playbookIn 1934, a legal government maneuver transferred billions in wealth overnight. Most Americans never saw it coming — but those who did walked away wealthy.Trump holds that same legal authority today. Advisors close to the administration believe he may use it.If he does, the transfer moves fast. The window to position yourself on the right side is already closing.June 15 at 1:00 AM | American Alternative (Ad)Alimera Sciences Inc.March 19, 2025 | money.usnews.comANI Pharmaceuticals’ Record Growth and Strategic AcquisitionNovember 9, 2024 | markets.businessinsider.comANI Pharmaceuticals’ Acquisition of Alimera Sciences Bolsters Buy Rating and $94 Target PriceSeptember 18, 2024 | markets.businessinsider.comAlimera Sciences, Inc. (NASDAQ:ALIM): When Will It Breakeven?September 12, 2024 | finance.yahoo.comAlimera Sciences, Inc. (ALIM)September 11, 2024 | finance.yahoo.comSee More Headlines ALIM Stock Analysis - Frequently Asked Questions How were Alimera Sciences' earnings last quarter? Alimera Sciences, Inc. (NASDAQ:ALIM) released its quarterly earnings data on Tuesday, August, 6th. The biopharmaceutical company reported ($0.06) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.04) by $0.02. The biopharmaceutical company had revenue of $27 million for the quarter, compared to analyst estimates of $25.76 million. Alimera Sciences had a negative trailing twelve-month return on equity of 33.70% and a negative net margin of 14.74%. When did Alimera Sciences' stock split? Alimera Sciences shares reverse split on the morning of Friday, November 15th 2019.The 1-15 reverse split was announced on Thursday, November 7th 2019. The number of shares owned by shareholders was adjusted after the market closes on Thursday, November 14th 2019. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. When did Alimera Sciences IPO? Alimera Sciences (ALIM) raised $0 in an initial public offering on Thursday, April 22nd 2010. The company issued 0 shares at $15.00-$17.00 per share. What other stocks do shareholders of Alimera Sciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Alimera Sciences investors own include Advanced Micro Devices (AMD), Tesla (TSLA), Meta Platforms (META), Netflix (NFLX), NVIDIA (NVDA), JPMorgan Chase & Co. (JPM) and Alphabet (GOOG). Company Calendar Last Earnings8/06/2024Today6/15/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ALIM CIK1267602 Webwww.alimerasciences.com Phone(678) 990-5740Fax678-990-5744Employees150Year Founded2003Profitability EPS (Trailing Twelve Months)($1.57) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$20.13 million Net Margins-14.74% Pretax Margin-14.76% Return on Equity-33.70% Return on Assets-9.63% Debt Debt-to-Equity Ratio1.80 Current Ratio2.79 Quick Ratio2.62 Sales & Book Value Annual Sales$99.68 million Price / Sales2.91 Cash FlowN/A Price / Cash FlowN/A Book Value$0.88 per share Price / Book6.30Miscellaneous Outstanding Shares52,389,000Free Float35,939,000Market Cap$290.24 million OptionableNo Data Beta1.25 Social Links Options Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free Report This page (NASDAQ:ALIM) was last updated on 6/15/2026 by MarketBeat.com Staff. From Our PartnersThe 1934 playbookIn 1934, a legal government maneuver transferred billions in wealth overnight. Most Americans never saw it com...American Alternative | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredIs SpaceX really worth 1.78 Trillion?With SpaceX approaching a near-$2 trillion valuation, most investors are focused on the IPO itself - but analy...InvestPub | SponsoredTrump Takes Emergency Action - Plus Elon Musk's New VentureElon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...Altimetry | SponsoredHey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...Banyan Hill Publishing | SponsoredCODE RED: AI Meltdown Imminent?After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...Paradigm Press | SponsoredSpaceX is chump change compared to Elon’s $20T ‘iPhone’Early Apple investors saw peak gains as high as 7,537% after the iPhone launched. Now, multiple insider source...StocksToTrade | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alimera Sciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Alimera Sciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ALIM Stock Alerts